Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Enzyme for the Treatment of Osteosarcoma and Merkel Cell Carcinoma: Potential for the Development of a Targeted Therapeutic Strategy
Biomolecules · 2025
DOI: 10.3390/biom15111553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Veronica Pompei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy. Hauptthemen laut MEDLINE: Osteosarcoma, Nicotinamide N-Methyltransferase, Carcinoma, Merkel Cell, Enzyme Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nicotinamide N-methyltransferase (NNMT) enzyme catalyzes the N-methylation of nicotinamide and its overexpression has been reported in many neoplasms, favoring traits featuring an aggressive tumor cell phenotype. Our recent data demonstrated that NNMT upregulation in osteosarcoma (OS) and Merkel cell carcinoma (MCC) led to a significant increase in cell proliferation and migration ability, together with a reduction in sensitivity to chemotherapeutic treatment. Based on these findings, we investigated the impact of small molecule NNMT inhibitors 5-amino-1-methyl quinolinium (5-AMQ), 6-methoxynicotinamide (6MeONa) and Eli Lilly’s pyrimidine 5-carboxamide (EL-1) on U-2 OS and Saos-2 OS cell lines and MCC13 and MCC26 MCC cell lines. Following incubation of the cells with these compounds, cell viability, reactive oxygen species (ROS) production and apoptosis induction were evaluated. Cells were then subjected to combined treatment with inhibitors and cisplatin (CDDP), and viability and ROS levels were further analyzed. Our results clearly illustrate that cells treated with NNMT inhibitors underwent significant reductions in viability, increased ROS production and activation of apoptotic pathways. Given the association of NNMT with cancer aggressiveness, inhibiting its catalytic activity might present a novel strategy for counteracting cancer growth and chemoresistance, providing the rationale for an effective anti-cancer therapy based on the use of specific NNMT inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy.
- Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, 00166 Rome, Italy.
- Biological Chemistry Group, Institute of Biology, Leiden University, 2311 Leiden, The Netherlands.
- New York-Marche Structural Biology Center (NY-MaSBiC), Polytechnic University of Marche, 60121 Ancona, Italy.
ORCID-Profile: Roberto Campagna, Valentina Pozzi, Davide Sartini
Zitieren
APA
Pompei, V., Cecati, M., Serritelli, E. N., Gerini, E., Campagna, R., Pozzi, V., Van Haren, M. J., Martin, N. I., Emanuelli, M., & Sartini, D. (2025). Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Enzyme for the Treatment of Osteosarcoma and Merkel Cell Carcinoma: Potential for the Development of a Targeted Therapeutic Strategy. Biomolecules. https://doi.org/10.3390/biom15111553
Vancouver
Pompei V, Cecati M, Serritelli EN, Gerini E, Campagna R, Pozzi V, et al. Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Enzyme for the Treatment of Osteosarcoma and Merkel Cell Carcinoma: Potential for the Development of a Targeted Therapeutic Strategy. Biomolecules. 2025. doi:10.3390/biom15111553
BibTeX
@article{Pompei2025,
author = {Pompei, Veronica and Cecati, Monia and Serritelli, Emma Nicol and Gerini, Eleonora and Campagna, Roberto and Pozzi, Valentina and Van Haren, Matthijs J and Martin, Nathaniel I and Emanuelli, Monica and Sartini, Davide},
title = {Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Enzyme for the Treatment of Osteosarcoma and Merkel Cell Carcinoma: Potential for the Development of a Targeted Therapeutic Strategy},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15111553}
}
EUVIMED